Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026. Management will engage with investors and analysts during a Fireside Chat scheduled for 11:30 a.m. Eastern Time. The event provides a platform for the company to discuss its strategic outlook and operational performance with the investment community.

The presentation will be accessible to stakeholders through a live audio webcast hosted on Johnson & Johnson's Investor Relations website at www.investor.jnj.com . An archived edition of the session will be made available later that day for those unable to attend live. Additionally, an audio webcast replay will be accessible approximately 48 hours after the initial broadcast.

Event Details

Contact Information

For media inquiries, contact media-relations@its.jnj.com . For investor relations inquiries, contact investor-relations@its.jnj.com .

Johnson & Johnson (NYSE: JNJ) has appointed Tom Cavanaugh as Executive Vice President and Worldwide Chairman of its Innovative Medicine division, effective September 1, 2026. Cavanaugh succeeds Jennifer Taubert, who is retiring after a tenure spanning more than 21 years. The leadership change impacts the company’s pharmaceutical segment, which generated more than $60 billion in annual revenue under Taubert’s oversight, marking a significant transition for one of the world’s largest healthcare businesses.

Cavanaugh currently serves as Company Group Chairman for North America within the Innovative Medicine division. He joins the Johnson & Johnson Executive Committee upon assuming his new role. Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, stated that Cavanaugh’s deep understanding of the business and proven track record of growth will ensure continued delivery for patients and healthcare systems. Duato emphasized that Cavanaugh’s focus on developing people positions the company to advance its pipeline and bring transformative medicines to market globally.

Leadership Transition Details

The appointment follows Taubert’s announcement of her retirement, concluding a career defined by leadership in global commercial strategy, acquisitions, and therapeutic area development. During her tenure, Taubert oversaw the expansion of the Innovative Medicine business across oncology, immunology, neuroscience, and cardiovascular disease. She was recognized for 10 consecutive years among Fortune’s Most Powerful Women and played a pivotal role in shaping the company’s reputation as an innovation-driven healthcare provider.

Cavanaugh brings nearly three decades of biopharmaceutical experience to the position. He joined Johnson & Johnson in 2017, holding senior leadership roles in Oncology, Immunology, and Global Commercial Strategy. Most recently, he led the company’s largest commercial region, driving growth and strengthening execution. Prior to his time at Johnson & Johnson, Cavanaugh spent nearly 15 years at Celgene, where he held roles in global product development, medical affairs, and marketing in Spain and the U.S.

Strategic Implications

The transition ensures continuity in the leadership of Johnson & Johnson’s most significant revenue-generating segment. The Innovative Medicine division accounts for a substantial portion of the company’s total revenue, having grown to more than $60 billion under Taubert’s leadership. Cavanaugh’s background in leading large-scale commercial operations and his experience across multiple therapeutic areas are expected to support the ongoing development and commercialization of the company’s pipeline.

Joaquin Duato noted that Taubert’s vision and commitment to healthcare innovation helped define an era of growth for the company. Her contributions included transforming the business in North America and advancing discussions on healthcare access and patient outcomes. As Cavanaugh assumes the chairmanship, the focus remains on maintaining the division’s position as one of the most respected pharmaceutical businesses globally while continuing to address unmet medical needs through innovation.